Volume 30, Number 8—August 2024
Dispatch
Crimean-Congo Hemorrhagic Fever Virus Kinetics in Serum, Saliva, and Urine, Iran, 2018
Malihe Metanat, Seyed Dawood Mousavi Nasab, Tahmineh Jalali, Fahimeh Bagheri Amiri, Neda Sadat Torab Jahromi, Mahsa Tavakoli, Mohammad Hassan Pouriayevali, Mohammad Mehdi Gouya, and Mostafa Salehi-Vaziri
Table
Positivity rate for Crimean-Congo hemorrhagic fever virus by real-time reverse transcription PCR and ELISA in serum, saliva, and urine samples from patients in Iran
| Days after disease onset | PCR-positive samples (%) |
Antigen ELISA–positive samples (%) |
IgM ELISA–positive serum samples (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Serum | Saliva | Urine | Serum | Saliva | Urine | |||
| 0–4 | 20/20 (100) | 5/9 (55.6) | 1/12 (8.3) | 7/7 (100) | 0/9 (0) | 0/11 (0) | 6/18 (33.3) | |
| 5–9 | 10/11 (90.9) | 15/19 (78.9) | 1/20 (5) | 1/6 (16.7) | 2/20 (10) | 0/21 (0) | 12/13 (92.3) | |
| 10–14 | 4/4 (100) | 5/6 (83.3) | 1/7 (14.3) | 0/4 (0) | 0/7 (0) | 0/7 (0) | 4/4 (100) | |
| ≥15 | 1/4 (25) | 0/3 (0) | 0/3 (0) | 0/4 (0) | 0/3 (0) | 0/3 (0) | Not tested | |
Page created: June 21, 2024
Page updated: July 29, 2024
Page reviewed: July 29, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.